Abbott and the Abbott Fund donate $1 million to support Hurricane Harvey relief efforts

AbbottAbbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver immediate relief following Hurricane Harvey and the devastating flooding affecting Texas and Louisiana. The Abbott Fund is providing $900,000 in grants to the American Red Cross, Americares and Direct Relief. Abbott is donating $100,000 in healthcare and nutrition products to relief organizations providing on-the-ground support in affected communities.

These donations build on earlier work with our partners Direct Relief and Feeding America to help communities prepare for the 2017 hurricane season. Abbott nutrition and healthcare products were stored at health clinics and food banks in advance of hurricane season, including in Louisiana and Texas. As a result, these clinics and food banks were able to quickly respond to meet immediate needs following Hurricane Harvey. For more information on our hurricane prep efforts, click here.

"Our thoughts are with everyone affected by Hurricane Harvey, and the many people and organizations working to help families in the affected communities," said Miles D. White, chairman and chief executive officer, Abbott. "Abbott and the Abbott Fund are working together with trusted relief organizations to help meet immediate needs today, and to help communities recover after the storm."

About Abbott and the Abbott Fund
As part of its commitment to helping people build better lives and stronger communities, Abbott has a long history of providing humanitarian relief around the world. Over the past decade, Abbott and its foundation the Abbott Fund have provided more than $40 million in funding and products to help meet both immediate needs and support long-term recovery efforts. In recent years, this included a rapid response to earthquakes in Chile, China and Haiti, typhoons in the Philippines and Vietnam, and hurricanes in the U.S.

At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

The Abbott Fund is a philanthropic foundation established by Abbott in 1951. The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]